Quick-Neuron GABAergic for Alzheimer's, Parkinson, Huntington's disease, and ALS

BALTIMORE, Nov. 27, 2017 – Elixirgen Scientific’s new GABAergic neuron differentiation kit can make global Alzheimer’s disease, Parkinson’s disease, and other brain disease research faster and better. The Baltimore biotech company today released Quick-Neuron™ GABAergic with two options using Sendai Virus (SeV) technology and synthetic mRNA. Quick-Neuron™ GABAergic will help scientists create GABAergic neurons in only 10 days. GABAergic neurons are also available through Elixirgen Scientific’s cell differentiation services.

These kits are a part of the Quick-TissueTM Series – a revolutionary new way to generate human cells, tissues, and organs. The Quick-Tissue™ Series kits’ potent cocktails of transcription factors transform researchers’ stem cells of choice into high-quality and homogeneous tissues in a scalable, speedy manner. The addition of the GABAergic neuron kits to the existing Cholinergic and Dopaminergic neuron kits will advance global neurodegenerative disease research. All kits will fit into wide variety of applications such as drug toxicity screening, drug discovery, 3D bioprinting, tissue chips, and creating mini-brains.